Literature DB >> 23291918

Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype.

Ei Yamaki1, Toshiki Yajima, Takayuki Kosaka, Akira Mogi, Shigebumi Tanaka, Hiroyuki Kuwano.   

Abstract

Podoplanin, a small type I integral membrane mucin-type sialoglycoprotein, serves as a useful marker for diagnosing malignant pleural mesothelioma (MPM); however, the physiological function of podoplanin in mesothelioma cells is not known. To elucidate the role of podoplanin in the pathogenesis of MPM, we generated two mesothelioma cell lines (PODO1 and PODO2) that stably express high levels of podoplanin. Although PODO1 cells proliferated to the same extent in culture or in nude mice, the survival rate of the mice was significantly reduced compared with that of the controls. We demonstrated that PODO1 and PODO2 cells had increased invasive ability in in vitro assays and induced upregulation of matrix metalloproteinase-1. PODO1 and PODO2 cultures could not be induced to undergo apoptosis when starved or treated with cis-diamminedichloroplatinum(II) (CDDP) compared with the controls. Moreover, silencing of podoplanin expression using RNA interference restored the ability of CDDP to induce apoptosis. Consistent with their growth properties, we detected constitutive activation of extracellular signal-regulated kinase in PODO1 and PODO2 cultures. These findings suggest that constitutive expression of podoplanin contributes to the invasive growth properties of mesothelioma cells and their resistance to apoptosis. Moreover, our data suggest that podoplanin or components of its signaling pathway, or both, may serve as important targets for developing novel treatments for MPM.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23291918     DOI: 10.3892/or.2013.2225

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Malignant mesothelioma: development to therapy.

Authors:  Joyce K Thompson; Catherine M Westbom; Arti Shukla
Journal:  J Cell Biochem       Date:  2014-01       Impact factor: 4.429

2.  Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma.

Authors:  Amanda L Hudson; Chris Weir; Elizabeth Moon; Rozelle Harvie; Sonja Klebe; Stephen J Clarke; Nick Pavlakis; Viive M Howell
Journal:  Sci Rep       Date:  2014-08-21       Impact factor: 4.379

3.  Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.

Authors:  Elly Marcq; Jorrit De Waele; Jonas Van Audenaerde; Eva Lion; Eva Santermans; Niel Hens; Patrick Pauwels; Jan P van Meerbeeck; Evelien L J Smits
Journal:  Oncotarget       Date:  2017-09-21

4.  Association of high PDPN expression with pulmonary metastasis of osteosarcoma and patient prognosis.

Authors:  Xincheng Wang; Wei Li; Jiaqi Bi; Jia Wang; Linying Ni; Qingtao Shi; Qinggang Meng
Journal:  Oncol Lett       Date:  2019-11-05       Impact factor: 2.967

5.  Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.

Authors:  Shinji Takeuchi; Koji Fukuda; Tadaaki Yamada; Sachiko Arai; Satoshi Takagi; Genichiro Ishii; Atsushi Ochiai; Shotaro Iwakiri; Kazumi Itoi; Hisanori Uehara; Hiroshi Nishihara; Naoya Fujita; Seiji Yano
Journal:  Cancer Sci       Date:  2017-04-12       Impact factor: 6.716

6.  Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma.

Authors:  Chao Sun; Liming Xiao; Yuanlin Zhao; Jiankuan Shi; Yuan Yuan; Yu Gu; Feng Zhang; Xing Gao; Ying Yang; Risheng Yang; Junhui Qin; Jin Zhang; Chao Wang; Yingmei Wang; Zhe Wang; Peizhen Hu; Ting Chang; Liang Wang; Gang Wang; Huangtao Chen; Zhuyi Li; Jing Ye
Journal:  Transl Oncol       Date:  2020-03-21       Impact factor: 4.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.